These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors. VanOosten RL; Earel JK; Griffith TS Cancer Gene Ther; 2006 Jun; 13(6):628-32. PubMed ID: 16456549 [TBL] [Abstract][Full Text] [Related]
3. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways. Shankar S; Singh TR; Fandy TE; Luetrakul T; Ross DD; Srivastava RK Int J Mol Med; 2005 Dec; 16(6):1125-38. PubMed ID: 16273296 [TBL] [Abstract][Full Text] [Related]
4. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Singh TR; Shankar S; Chen X; Asim M; Srivastava RK Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373 [TBL] [Abstract][Full Text] [Related]
5. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin. Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094 [TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Nakata S; Yoshida T; Horinaka M; Shiraishi T; Wakada M; Sakai T Oncogene; 2004 Aug; 23(37):6261-71. PubMed ID: 15208660 [TBL] [Abstract][Full Text] [Related]
9. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5. Frese S; Frese-Schaper M; Andres AC; Miescher D; Zumkehr B; Schmid RA Cancer Res; 2006 Jun; 66(11):5867-74. PubMed ID: 16740726 [TBL] [Abstract][Full Text] [Related]
10. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Cuello M; Ettenberg SA; Nau MM; Lipkowitz S Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126 [TBL] [Abstract][Full Text] [Related]
11. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma. Griffith TS; Fialkov JM; Scott DL; Azuhata T; Williams RD; Wall NR; Altieri DC; Sandler AD Cancer Res; 2002 Jun; 62(11):3093-9. PubMed ID: 12036919 [TBL] [Abstract][Full Text] [Related]
12. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells. Shiraishi T; Yoshida T; Nakata S; Horinaka M; Wakada M; Mizutani Y; Miki T; Sakai T Cancer Res; 2005 Jul; 65(14):6364-70. PubMed ID: 16024639 [TBL] [Abstract][Full Text] [Related]
13. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells. Izeradjene K; Douglas L; Delaney A; Houghton JA Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455 [TBL] [Abstract][Full Text] [Related]
14. Sensitization of human bladder tumor cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis with a small molecule IAP antagonist. Griffith TS; Kucaba TA; O'Donnell MA; Burns J; Benetatos C; McKinlay MA; Condon S; Chunduru S Apoptosis; 2011 Jan; 16(1):13-26. PubMed ID: 20734142 [TBL] [Abstract][Full Text] [Related]
15. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players. Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419 [TBL] [Abstract][Full Text] [Related]
17. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells. Lane D; Cartier A; L'Espérance S; Côté M; Rancourt C; Piché A Gynecol Oncol; 2004 Jun; 93(3):594-604. PubMed ID: 15196850 [TBL] [Abstract][Full Text] [Related]
18. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin. Mizutani Y; Nakao M; Ogawa O; Yoshida O; Bonavida B; Miki T J Urol; 2001 Jan; 165(1):263-70. PubMed ID: 11125422 [TBL] [Abstract][Full Text] [Related]
19. Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells. Shi RX; Ong CN; Shen HM Cancer Res; 2005 Sep; 65(17):7815-23. PubMed ID: 16140950 [TBL] [Abstract][Full Text] [Related]
20. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1). Chopin V; Slomianny C; Hondermarck H; Le Bourhis X Exp Cell Res; 2004 Aug; 298(2):560-73. PubMed ID: 15265702 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]